Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 26,900 shares, an increase of 67.1% from the November 30th total of 16,100 shares. Based on an average daily volume of 63,300 shares, the short-interest ratio is currently 0.4 days.
Hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP purchased a new stake in Opiant Pharmaceuticals during the third quarter valued at about $1,314,000. Two Sigma Advisers LP acquired a new position in shares of Opiant Pharmaceuticals during the third quarter worth about $2,139,000. BlackRock Inc. lifted its stake in shares of Opiant Pharmaceuticals by 107.2% during the third quarter. BlackRock Inc. now owns 24,686 shares of the technology company’s stock worth $635,000 after purchasing an additional 12,774 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Opiant Pharmaceuticals by 7.5% during the third quarter. Renaissance Technologies LLC now owns 205,615 shares of the technology company’s stock worth $5,293,000 after purchasing an additional 14,300 shares in the last quarter. Finally, Advisor Group Holdings Inc. lifted its stake in shares of Opiant Pharmaceuticals by 102.4% during the third quarter. Advisor Group Holdings Inc. now owns 6,325 shares of the technology company’s stock worth $163,000 after purchasing an additional 3,200 shares in the last quarter. 19.98% of the stock is owned by hedge funds and other institutional investors.
Separately, Oppenheimer initiated coverage on Opiant Pharmaceuticals in a research report on Wednesday, December 8th. They issued an “outperform” rating and a $42.00 price objective for the company.
Shares of NASDAQ:OPNT traded down $0.87 during midday trading on Monday, reaching $32.76. The company’s stock had a trading volume of 1,151 shares, compared to its average volume of 73,239. The firm has a market cap of $154.63 million, a price-to-earnings ratio of 672.73 and a beta of 0.50. The company has a quick ratio of 9.23, a current ratio of 9.23 and a debt-to-equity ratio of 0.45. Opiant Pharmaceuticals has a 1 year low of $7.95 and a 1 year high of $37.71. The business has a 50 day moving average price of $28.63 and a 200 day moving average price of $22.16.
Silicon Valley millionaire Jeff Brown called it in 2014, when he first bought Bitcoin.
In 2016, he recommended Nvidia at $25… before it hit $799… and he predicted the #1 returning tech stock in 4 years out of 5…
Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings results on Thursday, November 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.41. Opiant Pharmaceuticals had a return on equity of 4.25% and a net margin of 3.58%. During the same quarter in the prior year, the firm earned $0.15 earnings per share. Sell-side analysts anticipate that Opiant Pharmaceuticals will post 0.39 earnings per share for the current fiscal year.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.
Featured Article: What is the strike price in options trading?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Opiant Pharmaceuticals right now?
Before you consider Opiant Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Opiant Pharmaceuticals wasn’t on the list.
While Opiant Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Up 67.1% in December